Related Experiment Video
Updated: Nov 2, 2025

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Evaluation of compounded trilostane packets for dogs with naturally occurring hyperadrenocorticism
Sookin Nam1, Tae-Won Kim1, Kun-Ho Song1
1College of Veterinary Medicine, Chungnam National University, Deajeon, South Korea.
Background:
Dogs treated for naturally occurring hyperadrenocorticism (NOH) in Korea often appear to require higher doses of trilostane than recommended by authors in the United States, Europe, or the United Kingdom. This phenomenon may be related to compounding trilostane into packets, which is a common practice among veterinary clinics in Korea.
Objective:
Analyze packets filled by hand and others filled using a semi-automatic packing device for accuracy of trilostane strength.
Animals:
Medication packets prepared for 3 dogs with preexisting prescriptions for NOH were analyzed.
Method:
A trilostane assay was developed for analysis. Trilostane (Vetoryl) capsules were used as clinical controls. Forty-four medication packets containing trilostane (Vetoryl), prepared by 3 clinicians for 3 dogs with NOH were analyzed.
Results:
Of 44 trilostane-containing packets, only 40.9% (18 packets) had acceptable strength of trilostane.
Conclusions And Clinical Importance:
Clinicians should be aware that compounding trilostane into packets fails to consistently provide measured amounts of trilostane, potentially interfering with response to treatment for NOH in dogs.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

